larger balls required, page-15

ITs possible. Good thinking dossandt. Hit the market this week with ICS and Monday week with the interim CAN003. Fantastic! Pure speculation though lol, but we wont be far out given that the company advised ICS early October and interim results by Monday week. If Dr Goh presents on the 15th that will be Monday night in Canada so impact on our market would be on the Tuesday. They may decide to release the text of the presentation beforehand but I would think we would need Dr Gohs full commentary to glean what it all means.

SYDNEY, AUSTRALIA--(Marketwire - Jul 29, 2012) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (Prima, the Company) announces that it will be releasing interim results from its CVac™ clinical trial CAN-003 in October 2012.
The International Gynecologic Cancer Society (IGCS) has accepted an abstract by Dr. Jeffrey Goh et al. entitled "Clinical study of autologous dendritic cell therapy targeting mucin 1 for treatment of ovarian cancer in first or second remission" for a poster presentation at its biennial meeting in Vancouver, Canada from October 13-16, 2012.
Dr. Goh's poster will present interim safety and progression-free survival (PFS) data from the CAN-003 trial based on a currently ongoing analysis.

Expected CAN-003 study data timetable:
October 2012: Final (63rd) patient receives final dose of CVac
Early October 2012: ICS data from the first 6 patients who completed dosing
October 15 2012: Interim safety and PFS data presented by Dr. Goh at the IGCS conference in Vancouver, Canada.
Throughout 2013: Updates on ICS data from subsequent cohorts of patients.
4th Quarter 2013: Final data analysis per protocol of safety, PFS, and other endpoints.